American Cancer Society (2021) Cancer Facts & Figures 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed 18 May 2022

European Medicines Agency (2020) Guideline on the clinical evaluation of anticancer medicinal products. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf. Accessed 18 May 2022

De Jongh FE, Verweij J, Loos WJ et al (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733–3739. https://doi.org/10.1200/JCO.2001.19.17.3733

Article  PubMed  Google Scholar 

Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86:1297–1302. https://doi.org/10.1038/sj.bjc.6600139

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chatelut E, White-Koning ML, Mathijssen RH et al (2012) Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 107:1100–1106. https://doi.org/10.1038/bjc.2012.357

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Dingemans A-MC, Früh M, Ardizzoni A et al (2021) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 32:839–853. https://doi.org/10.1016/j.annonc.2021.03.207

Article  PubMed  Google Scholar 

Faivre-Finn C, Snee M, Ashcroft L et al (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116–1125. https://doi.org/10.1016/S1470-2045(17)30318-2

Article  PubMed  PubMed Central  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6

Article  PubMed  CAS  Google Scholar 

Chen R, Li J, Hu WW et al (2013) Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program. Cancer Chemother Pharmacol 72:1111–1123. https://doi.org/10.1007/s00280-013-2288-5

Article  PubMed  CAS  Google Scholar 

de Jongh FE, Gallo JM, Shen M et al (2004) Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 54:105–112. https://doi.org/10.1007/s00280-004-0790-5

Article  PubMed  Google Scholar 

Morita-Ogawa T, Sugita H, Minami H et al (2020) Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction. Cancer Chemother Pharmacol 86:559–566. https://doi.org/10.1007/s00280-020-04147-4

Article  PubMed  CAS  Google Scholar 

Nagai N, Ogata H, Wada Y et al (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 38:1025–1034

Article  CAS  Google Scholar 

Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756–763. https://doi.org/10.1111/j.1365-2125.2004.02082.x

Article  PubMed  PubMed Central  CAS  Google Scholar 

Urien S, Brain E, Bugat R et al (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55–60. https://doi.org/10.1007/s00280-004-0852-8

Article  PubMed  CAS  Google Scholar 

Darwich AS, Ogungbenr K, Hatley OJ, Rostami-Hodjegan A (2017) Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res 6:S1512–S1529. https://doi.org/10.21037/tcr.2017.09.14

Article  CAS  Google Scholar 

Loos WJ, De Jongh FE, Sparreboom A et al (2006) Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 24:1499–1506. https://doi.org/10.1200/JCO.2005.03.0056

Article  PubMed  CAS  Google Scholar 

Puisset F, Schmitt A, Chatelut E (2014) Standardization of chemotherapy and individual dosing of platinum compounds. Anticancer Res 34:465–470

PubMed  CAS  Google Scholar 

Schellens JHM, Ma J, Planting AST et al (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569–1575. https://doi.org/10.1038/bjc.1996.296

Article  PubMed  PubMed Central  CAS  Google Scholar 

Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage:prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756. https://doi.org/10.1200/JCO.1989.7.11.1748

Article  PubMed  CAS  Google Scholar 

Kasi PM, Grothey A (2018) Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs 78:737–745. https://doi.org/10.1007/s40265-018-0909-3

Article  PubMed  Google Scholar 

Kasi PM, Grothey A (2020) Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Ann Oncol 31:15–16. https://doi.org/10.1016/j.annonc.2019.11.001

Article  PubMed  CAS  Google Scholar 

Yoshino T, Cleary JM, Van Cutsem E et al (2020) Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol 31:88–95. https://doi.org/10.1016/j.annonc.2019.10.005

Article  PubMed  CAS  Google Scholar 

Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669–677. https://doi.org/10.1016/S1470-2045(05)70255-2

Article  PubMed  CAS  Google Scholar 

ter Heine R, Keizer RJ, van Steeg K et al (2020) Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol 86:2497–2506. https://doi.org/10.1111/bcp.14360

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao W, Kaguelidou F, Biran V et al (2013) External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 75:1068–1080. https://doi.org/10.1111/j.1365-2125.2012.04406.x

Article  PubMed  CAS  Google Scholar 

Guo T, van Hest RM, Roggeveen LF et al (2019) External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients. Antimicrob Agents Chemother 63:1–9. https://doi.org/10.1128/AAC.02543-18

Article  Google Scholar 

Chan Kwong A, O’Jeanson A, Khier S (2021) Model-informed therapeutic drug monitoring of meropenem in critically Ill patients: improvement of the predictive ability of literature models with the PRIOR approach. Eur J Drug Metab Pharmacokinet 46:415–426. https://doi.org/10.1007/s13318-021-00681-5

Article  PubMed  CAS  Google Scholar 

Chan Kwong AHXP, Calvier EAM, Fabre D et al (2020) Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn 47:431–446. https://doi.org/10.1007/s10928-020-09695-z

Article  PubMed  PubMed Central  Google Scholar 

Wright JG, Boddy AV, Highley M et al (2001) Estimation of glomerular filtration rate in cancer patients. BrJCancer 84:452–459. https://doi.org/10.1054/bjoc.2000.1643

Article  CAS  Google Scholar 

Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098–1098. https://doi.org/10.1056/NEJM198710223171717

Article  PubMed  CAS  Google Scholar 

Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29:473–505. https://doi.org/10.1023/a:1022972420004

Article  PubMed  Google Scholar 

Morley SK, Brito TV, Welling DT (2018) Measures of model performance based on the log accuracy ratio. Sp Weather 16:69–88. https://doi.org/10.1002/2017SW001669

Article  Google Scholar 

Schräpel C, Kovar L, Selzer D et al (2021) External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13091368

Article  PubMed  PubMed Central  Google Scholar 

Hanafin PO, Nation RL, Scheetz MH et al (2021) Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT pharmacometrics Syst Pharmacol 10:1525–1537. https://doi.org/10.1002/psp4.12720

Article  PubMed  PubMed Central  CAS  Google Scholar 

Konecki C, Feliu C, Cazaubon Y et al (2021) External evaluation of population pharmacokinetic models and Bayes-based dosing of infliximab. Pharmaceutics 13:1191. https://doi.org/10.3390/pharmaceutics13081191

Article  PubMed  PubMed Central  CAS  Google Scholar 

Corral Alaejos Á, Zarzuelo Castañeda A, Jiménez Cabrera S et al (2021) External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15122

Article  PubMed  Google Scholar 

Faivre C, El Cheikh R, Barbolosi D, Barlesi F (2017) Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients. Br J Cancer 116:344–348. https://doi.org/10.1038/bjc.2016.439

Article  PubMed  PubMed Central  CAS